Novavax Inc:Results From Novavax Nanoflu Influenza Vaccine Phase 3 Clinical Trial Published In Lancet Infectious Diseases.Novavax - Results From Nanoflu Influenza Vaccine Phase 3 Clinical Trial Achieved All Primary Endpoints.Novavax Inc - Nanoflu Vaccine Candidate Induced Significantly Enhanced Cell-Mediated Immune Responses.Novavax Inc - Nanoflu Was Well-Tolerated With A Comparable Safety Profile.
精彩评论